利伐沙班对比依诺肝素对急性冠脉综合征急性期主要心脏不良事件及出血风险的影响:H-REPLACE 随机等效性与非劣效性试验
该多中心、前瞻性、开放标签、活性对照的等效性与非劣效性试验于2017年1月至2021年5月在中国21家医院开展,纳入错过主要再灌注时间窗或择期血运重建前的急性冠脉综合征患者,随机接受口服利伐沙班2.5 mg、5 mg或皮下依诺肝素1 mg/kg(每日两次),均联用双联抗血小板治疗(阿司匹林100 mg与氯吡格雷75 mg每日一次),平均用药3.7天,随访6个月。主要安全终点出血发生率:依诺肝素组6.8%、利伐沙班2.5 mg组4.7%、利伐沙班5 mg组5.3%;利伐沙班2.5 mg与5 mg对比依诺肝素的非劣效HR分别为0.68(95%CI 0.43-1.07,P=.005)和0.88(95%CI 0.70-1.09,P=.001)。主要疗效终点MACE三组相似,利伐沙班5 mg组非劣效达标(HR 0.60,95%CI 0.31-1.16,P=.02),利伐沙班2.5 mg组未达标(HR 0.68,95%CI 0.36-1.30,P=.05)。作者认为该可行性研究结果为设计足够样本量的未来随机临床试验提供了有用信息。
要点
- 急性冠脉综合征急性期联用双联抗血小板治疗时,口服利伐沙班5 mg在出血方面非劣效于皮下依诺肝素1 mg/kg每日两次(HR 0.88,95%CI 0.70-1.09,P=.001)。
- 利伐沙班5 mg的MACE非劣效性达标(HR 0.60,95%CI 0.31-1.16,P=.02),利伐沙班2.5 mg未达标(HR 0.68,95%CI 0.36-1.30,P=.05)。
- 出血发生率:依诺肝素组6.8%(46例)、利伐沙班2.5 mg组4.7%(32例)、利伐沙班5 mg组5.3%(36例)。
- 利伐沙班2.5 mg出血非劣效HR 0.68(95%CI 0.43-1.07,P=.005)。
- 作者认为该可行性研究结果为设计足够样本量的未来随机临床试验提供了有用信息。
适用人群与场景
- 纳入错过主要再灌注时间窗或择期血运重建前的急性冠脉综合征患者,来自中国21家医院,平均年龄65.8岁(SD 8.2),男性1443例(70.5%)。
处置流程与药物剂量
- 随机1:1:1接受口服利伐沙班2.5 mg或5 mg,或皮下依诺肝素1 mg/kg每日两次,均联用双联抗血小板治疗(阿司匹林100 mg与氯吡格雷75 mg每日一次),平均用药3.7天。
研究设计与关键结果
- 多中心、前瞻性、开放标签、活性对照的等效性与非劣效性试验,2017年1月至2021年5月在中国21家医院开展,随访6个月;2055例入组,2046例(99.6%)完成试验,随机分为依诺肝素组680例、利伐沙班2.5 mg组683例、利伐沙班5 mg组683例。
- 主要安全终点出血(国际血栓与止血学会定义):依诺肝素组46例(6.8%)、利伐沙班2.5 mg组32例(4.7%)、利伐沙班5 mg组36例(5.3%);利伐沙班2.5 mg vs 依诺肝素非劣效HR 0.68(95%CI 0.43-1.07,P=.005),利伐沙班5 mg vs 依诺肝素非劣效HR 0.88(95%CI 0.70-1.09,P=.001)。
- 主要疗效终点MACE(包括心源性死亡、心肌梗死、再次血运重建或卒中,6个月随访)三组发生率相似;利伐沙班5 mg组非劣效达标(HR 0.60,95%CI 0.31-1.16,P=.02),利伐沙班2.5 mg组未达标(HR 0.68,95%CI 0.36-1.30,P=.05)。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、开放标签、活性对照的等效性与非劣效性随机试验。
- 局限:作者称该研究为可行性研究,其结果可为设计足够样本量的未来随机临床试验提供有用信息。
对床旁实践的改变
- 作者认为,在急性冠脉综合征急性期接受双联抗血小板治疗的患者中,口服利伐沙班5 mg在出血方面非劣效于皮下依诺肝素1 mg/kg。
- 作者认为该可行性研究结果为设计足够样本量的未来随机临床试验提供了有用信息。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Parenteral enoxaparin is a preferred anticoagulant used in the acute phase for patients with acute coronary syndrome (ACS). The safety and efficacy of short-term low-dose rivaroxaban in this clinical setting remain unknown.
OBJECTIVE: To compare the safety and efficacy of rivaroxaban vs enoxaparin in the acute phase of ACS.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective, open-label, active-controlled, equivalence and noninferiority trial was conducted from January 2017 through May 2021 with a 6-month follow-up at 21 hospitals in China. Participants included patients with ACS missing the primary reperfusion window or before selective revascularization. Data were analyzed from November 2021 to November 2022.
INTERVENTIONS: Participants were randomized 1:1:1 to oral rivaroxaban 2.5 mg or 5 mg or 1 mg/kg subcutaneous enoxaparin twice daily in addition to dual antiplatelet therapy (DAPT; aspirin 100 mg and clopidogrel 75 mg once daily) for a mean of 3.7 days.
MAIN OUTCOMES AND MEASURES: The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up.
RESULTS: Of 2055 enrolled patients, 2046 (99.6%) completed the trial (mean [SD] age 65.8 [8.2] years, 1443 [70.5%] male) and were randomized to enoxaparin (680 patients), rivaroxaban 2.5 mg (683 patients), or rivaroxaban 5 mg (683 patients). Bleeding rates were 46 patients (6.8%) in the enoxaparin group, 32 patients (4.7%) in the rivaroxaban 2.5 mg group, and 36 patients (5.3%)in the rivaroxaban 5 mg group (rivaroxaban 2.5 mg vs enoxaparin: noninferiority hazard ratio [HR], 0.68; 95% CI, 0.43 to 1.07; P = .005; rivaroxaban 5 mg vs enoxaparin: noninferiority HR, 0.88; 95% CI, 0.70 to 1.09; P = .001). The incidence of MACEs was similar among groups, and noninferiority was reached in the rivaroxaban 5 mg group (HR, 0.60; 95% CI, 0.31 to 1.16, P = .02) but not in the rivaroxaban 2.5 mg group (HR, 0.68; 95% CI, 0.36 to 1.30; P = .05) compared with the enoxaparin group.
CONCLUSIONS AND RELEVANCE: In this equivalence and noninferiority trial, oral rivaroxaban 5 mg showed noninferiority to subcutaneous enoxaparin (1 mg/kg) for patients with ACS treated with DAPT during the acute phase. Results of this feasibility study provide useful information for designing future randomized clinical trials with sufficient sample sizes.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03363035.
参考来源
- Zhou S, Xiao Y, Zhou C, et al. Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. JAMA Netw Open. 2023. PMID: 36763358. doi:10.1001/jamanetworkopen.2022.55709
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。